By Maggie Fick BRUSSELS, June 23 (Reuters) - China has pulled ahead of Europe in pharmaceutical innovation and drug ...

By Deena Beasley SAN DIEGO, June 22 (Reuters) - China, which now conducts more clinical drug trials than the U.S., still lags ...

SpliSense is currently conducting a Phase IIb trial with its antisense oligonucleotide therapy.

The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against ...

Novel immune reprogramming oral macrocyclic peptides designed for precise modulation of complex biological networks involved in inflammatory, autoimmune and fibro-inflammatory diseases ...

Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

For four key projects, the companies will jointly develop the assets globally and co-commercialize them in the United States and Europe, sharing profits in those markets. Innovent will retain rights ...

After the deal closes, expected in the fourth quarter of this year, Altaris plans to combine Simulations Plus with its existing portfolio company, Chemical Computing Group, which ...

While biopharma’s overarching mission is to develop innovative medicines to improve patient outcomes, for these six people, ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

As pressure mounts globally on drug pricing and development cost continues to rise, clinicians and translational scientists in biotech, academia and biopharma companies are re-evaluating when, where ...